Benzinga’s Top Ratings Upgrades, Downgrades For September 13, 2022
Upgrades
See all analyst ratings upgrades.
Goldman Sachs Downgrades Infosys to Sell
Goldman Sachs analyst Sumeet Jain downgrades Infosys (NYSE:INFY) from Buy to Sell.
Argus Research Downgrades Tyson Foods to Hold
Argus Research analyst John Staszak downgrades Tyson Foods (NYSE:TSN) from Buy to Hold.
Truist Securities Downgrades AnaptysBio to Hold, Lowers Price Target to $28
Truist Securities analyst John Lee downgrades AnaptysBio (NASDAQ:ANAB) from Buy to Hold and lowers the price target from $50 to $28.
Credit Suisse Downgrades Oatly Group to Neutral, Lowers Price Target to $3.43
Credit Suisse analyst Kaumil Gajrawala downgrades Oatly Group (NASDAQ:OTLY) from Outperform to Neutral and lowers the price target from $6 to $3.43.
Jefferies Downgrades Dow to Hold, Lowers Price Target to $45
Jefferies analyst Laurence Alexander downgrades Dow (NYSE:DOW) from Buy to Hold and lowers the price target from $71 to $45.
‘More Difficult Environment’ Forces Bullish Analyst To Jump Ship On $180 Billion Tech Giant
Mizuho analyst Gregg Moskowitz downgraded Adobe Inc (NASDAQ:ADBE) to Neutral from Buy, and cut his Q4, FY23 estimates with a price target of…
B of A Securities Downgrades Neoleukin Therapeutics to Underperform, Announces $1 Price Target
B of A Securities analyst Greg Harrison downgrades Neoleukin Therapeutics (NASDAQ:NLTX) from Buy to Underperform and announces $1 price target.
Goldman Sachs Downgrades Oak Street Health to Neutral, Lowers Price Target to $29
Goldman Sachs analyst Jamie Perse downgrades Oak Street Health (NYSE:OSH) from Buy to Neutral and lowers the price target from $32 to $29.
Mizuho Downgrades Adobe to Neutral, Lowers Price Target to $440
Mizuho analyst Gregg Moskowitz downgrades Adobe (NASDAQ:ADBE) from Buy to Neutral and lowers the price target from $480 to $440.